TEST BANK FOR CLAYTON’S BASIC PHARMACOLOGY FOR
NURSES 19TH EDITIONBY MICHELLE J. WILLIHNGANZ,
SAMUEL L. GUREVITZ, BRUCE CLAYTON COMPLETE
,Chapter 01: Drug Definitions, Standards, and Information Sources Willihn
ganz: Clayton’s Basic Pharmacology for Nurses, 19th Edition
MULTIPLE CHOIC
E
1. Which name identifies a drug listed by the US Foo
d andDrug Administration (FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS: C
The official name is the name under which a drug is
listed by the FDA. The brand name, or trademark, is t
he name given to a drug by its manufacturer. The non
proprietary, or generic, name is provided by the United
States Adopted Names Council.
DIF: Cognitive t 6 Level: t 6 Knowledge REF: t 6 t 6 p. t 6 9
OBJ: t 6 1NAT: t 6 NCLEX t 6 Client t 6 Needs t 6 Category: t 6 Safe,
t 6 Effective t6CareEnvironment t 6 TOP: Nursing t 6 Process
t 6 Step: t 6 Assessment
CON:
Patient t 6 Education
2. Which t 6 source t 6 contains t 6 information t 6 specific t 6 to t 6 nutritional t 6 supplements?
a. USP t 6 Dictionary t 6 of t 6 USAN t 6 & t6International t 6 Drug t 6 Names
b. Natural t 6 Medicines t 6 Comprehensive t 6 Database
c. United t 6 States t 6 Pharmacopoeia/National t 6 Formulary t 6 (USP t 6 NF)
d. Drug t 6 Interaction t 6 Facts
ANS: t 6 C
United t6States t6Pharmacopoeia/National t6Formulary t6contains t6information t6specific t6to
t6nutriti t6onalsupplements. t 6 USP t 6 Dictionary t 6 of t 6 USAN t 6 & t 6 International t 6 Drug
t 6 Names t 6 is t 6 a t 6 compilat t6ion t 6 of t 6 drug8hnames, t 6 pronunciation t 6 guide, t 6 and
t 6 possible t 6 future t 6 FDA t 6 approved t 6 drugs; t 6 it t 6 d t6oes t6not t6include t6nutritional
t6supplements. t6Natural t6Medicines t6Comprehensive t6Database t6c t6ontains
evidence-
based t 6 information t 6 on t 6 herbal t 6 medicines t 6 and t 6 herbal t 6 combination t 6 products; t 6 it
t 6 does t 6 notincl t6ude t 6 information t 6 specific t 6 to t 6 nutritional t 6 supplements. t 6 Drug
t 6 Interaction t 6 Facts t 6 contains t 6 co t6mprehensive t 6 information t 6 on t 6 drug t 6 interaction
t 6 facts; t 6 it t 6 does t 6 not t 6 include t 6 nutritional t 6 supp t 6 lements.
DIF: Cognitive t 6 Level: t 6 Knowledge REF: p. t 6 4
OBJ: t 6 3NAT: t 6 NCLEX t 6 Client t 6 Needs t 6 Category:
t 6 Physiological t6Integrity
TOP: Nursing t 6 Process t 6 Step: t 6 Assessment t 6 CON: Nutrition t 6 | t 6 Patient t 6 Education
3. Which t 6 drug t 6 reference t 6 contains t 6 drug t 6 monographs t 6 that t 6 describe t 6 all t 6 drugs t 6 in t 6 a
therapeutic t 6 class?
t 6
a. Drug t 6 Facts t 6 and t 6 Comparisons
,Test t 6 Bank t 6 For t 6 Clayton’s t 6 Basic t 6 Pharmacology t 6 for 3
t 6 Nurses t 6 19th
b. Drug t 6 Interaction t 6 Facts
c. Handbook t 6 on t 6 Injectable t 6 Drugs
d. Martindale—The t 6 Complete t 6 Drug t 6 Reference
ANS: t 6 A
Drug t 6 Facts t 6 and t 6 Comparisons t 6 contains t 6 drug t 6 monographs t 6 that
t 6 describe t 6 all t 6 drug t6s t 6 in t 6 a8htherapeutic t 6 class. t 6 Monographs t 6 are
t 6 formatted t 6 as t 6 tables t 6 to t 6 allow t 6 compariso t6n t6of t6similarproducts, t6brand
t6names, t6manufacturers, t6cost t6indices, t6and t6available t6d t 6 osage t 6 forms t 6 Online
t 6 version t 6 is t 6 available.
DIF: Cognitive t 6 Level: t 6 Knowledge REF: p. t 6 4 t 6 Table t 6 1.2
OBJ: 3 NAT: t 6 t 6 NCLEX t 6 Client t 6 Needs t 6 Category: t 6 Physiological t 6 Integrity
TOP: Nursing t 6 Process t 6 Step: t 6 Assessment t 6 CON: Safety t 6 | t 6 Patient t 6 Education t 6 | t 6 Clinical
t 6 Judgment
4. Which t 6 drug t 6 reference t 6 contains t 6 monographs t 6 about t 6 virtually t 6 every t 6 single-
entity t6drug t 6 availablein t 6 the t 6 United t 6 States t 6 and t 6 describes t 6 therapeutic t 6 uses t 6 of
t 6 drugs, t 6 incl t6uding t 6 approved t 6 and t 6 unapproved t 6 uses?
a. Martindale: t 6 The t 6 Complete t 6 Drug t 6 Reference
b. AHFS t 6 Drug t 6 Information
c. Drug t 6 Reference
d. Drug t 6 Facts t 6 and t 6 Comparisons
ANS: t 6 B
AHFS t 6 Drug t 6 Information t 6 contains t 6 monographs t 6 about t 6 virtually t 6 every t 6 single-
entity t 6 drug t 6 available t 6 in t 6 the t 6 United t 6 States t 6 and t 6 describes t 6 therapeutic t 6 uses
t 6 of t 6 drugs, t 6 inclu t6ding t 6 approved t 6 and8hunapproved t 6 uses.
DIF: Cognitive t 6 Level: t 6 Knowledge REF: p. t 6 4 t 6 Table t 6 1.2
OBJ: 3 NAT: t 6 t 6 NCLEX t 6 Client t 6 Needs t 6 Category: t 6 Physiological t 6 Integrity
TOP: Nursing t 6 Process t 6 Step: t 6 Planning CON: Safety t 6 | t 6 Patient t 6 Education t 6 | t 6 Clinical
t 6 Judgment
5. Which t 6 online t 6 drug t 6 reference t 6 makes t 6 available t 6 to t 6 healthcare t 6 providers
and t 6 the t 6 publi t6c t 6 a t 6 standard, t 6 comprehensive, t 6 up-to-
t 6
date t 6 look t 6 up t 6 and t 6 downloadable t 6 resource t 6 about t 6 medicines?
a. American t 6 Drug t 6 Index
b. American t 6 Hospital t 6 Formulary
c. DailyMed
d. Drug t 6 Reference
ANS: t 6 C
DailyMed t6makes t6available t6to t6healthcare t6providers t6and t6the t6public t6a t6standard,
t6comprehe t6nsive,8hup-to-
date t 6 look t 6 up t 6 and t 6 downloadable t 6 resource t 6 about t 6 medicines. t 6 The t 6 American
t 6 Drug t 6 Index t 6 i t6snot t 6 appropriate t 6 for t 6 patient t 6 use. t 6 The t 6 American t 6 Hospital
t 6 Formulary t 6 is t 6 not t 6 appropriate t6for t 6 patient t 6 use. t 6 The t 6 drug t 6 reference
t 6 is t 6 not t 6 appropriate t 6 for t 6 patient t 6 use.
DIF: Cognitive t 6 Level: t 6 Knowledge REF: p. t 6 3 t 6 | t 6 p. t 6 4
OBJ: t 6 3NAT: t 6 NCLEX t 6 Client t 6 Needs t 6 Category:
t 6 Physiological t6Integrity
TOP: t 6 Nursing t 6 Process t 6 Step: t 6 Implementation
CON: t 6 t 6 Safety t 6 | t 6 Patient t 6 Education t 6 | t 6 Clinical t 6 Judgment
6. Which t 6 legislation t 6 authorizes t 6 the t 6 FDA t 6 to t 6 determine t 6 the t 6 safety t6of t 6 a t 6 drug t 6 before
its t 6 marketing?
t 6
a. Federal t 6 Food, t 6 Drug, t 6 and t 6 Cosmetic t 6 Act t 6 (1938)
b. Durham t 6 Humphrey t 6 Amendment t 6 (1952)
, Test t 6 Bank t 6 For t 6 Clayton’s t 6 Basic t 6 Pharmacology t 6 for 4
t 6 Nurses t 6 19th
c. Controlled t 6 Substances t 6 Act t 6 (1970)
d. Kefauver t 6 Harris t 6 Drug t 6 Amendment t 6 (1962)
ANS: t 6 A
The t 6 Federal t 6 Food, t 6 Drug, t 6 and t 6 Cosmetic t 6 Act t 6 of t 6 1938 t 6 authorized t 6 the
t 6 FDA t 6 to t 6 determine t 6 the t 6 safety t 6 of t 6 all t 6 drugs t 6 before t 6 marketing. t 6 Later
t 6 amendments t 6 and t 6 acts t 6 helped t 6 tighten t 6 FDA t 6 control t 6 and t 6 ensure t 6 drug
t 6 safety. t 6 The t 6 Durham t 6 Humphrey t 6 Amendment t 6 defines t 6 the t6kinds t 6 of t 6 drugs
t 6 that t 6 cannot t 6 be t 6 used t 6 safely t 6 without t 6 medical t 6 supervision t 6 and t 6 restricts t 6 th
t 6 eir t 6 sale t 6 to t 6 prescription t 6 by t 6 a t 6 licensed t 6 practitioner. t 6 The t 6 Controlled
t 6 Substances t 6 Act t 6 addre t6sses t 6 only t 6 controlled t 6 substances t 6 andtheir
t 6 categorization. t 6 The t 6 Kefauver t 6 Harris t 6 Drug t 6 Ame t6ndment t 6 ensures t 6 drug
t 6 efficacy t 6 and t 6 greaterdrug t 6 safety. t 6 Drug t 6 manufacturers t 6 are t 6 required t6to
t 6 prove t 6 to t 6 the t 6 FDA t 6 the t 6 effectiveness t 6 of t 6 their t 6 products t 6 before
t 6 marketing t 6 them.
DIF: Cognitive t6 Level: t6 Knowledge
REF: t 6 p. t 6 5 t6Table
t 6 l.3 t6OBJ: 5
NAT: t 6 NCLEX t 6 Client t 6 Needs t 6 Category: t6 Physiological t6 Inte
t6grity8hTOP: t 6 Nursing t 6 Process t 6 Step: t 6 Assessment
CON: Safety t 6 | t 6 Patient t 6 Education t 6 | t 6 Evidence t 6 | t 6 Health t 6 Care t 6 Law
7. Which t 6 classification t6 does t 6 meperidine t 6 (Demerol) t 6 fall t 6 under?
a. I
b. II
c. III
d. IV
ANS: t 6 B
Meperidine t 6 (Demerol) t 6 is t 6 a t 6 Schedule t 6 II t 6 drug; t 6 it t 6 has t 6 a t 6 high
t 6 potential t 6 for t 6 abuse t 6 and t 6 m t6ay t 6 lead t 6 tosevere t 6 psychological t 6 and t 6 physical
t 6 dependence. t 6 Schedule t 6 I t 6 drugs t 6 have t 6 high t 6 p t6otential t 6 for t 6 abuseand t 6 no
t 6 recognized t 6 medical t 6 use. t 6 Schedule t 6 III t 6 drugs t 6 have t 6 some t 6 potent t6ial t 6 for
t 6 abuse. t 6 Use t 6 may t 6 lead t 6 to t 6 low t 6 to t 6 moderate t 6 physical t 6 dependence t 6 or t 6 high
t 6 psychol t 6 ogical t 6 dependence. t 6 Schedule t 6 IVdrugs t 6 have t 6 low t 6 potential t 6 for
t 6 abuse. t 6 Use t 6 may t 6 lead t 6 to t 6 limited t 6 physical t 6 or t 6 psychological t 6 dependence.
DIF: Cognitive t 6 Level: t 6 Knowledge REF: p. t 6 10
OBJ: t 6 2NAT: t 6 NCLEX t 6 Client t 6 Needs t 6 Category:
t 6 Safe, t 6 Effectiv t 6 e t 6 Care t 6 Environment
TOP: Nursing t 6 Process t 6 Step: t 6 Assessment t 6 CON: Patient t 6 Education t 6 | t 6 Addiction t6 | t 6 Pain
8. Which t 6 action t 6 would t 6 the t 6 FDA t 6 take t 6 to t 6 expedite t 6 drug t 6 development t 6 and
t6approval t 6 for t 6 an t 6 o t6utbreakof t 6 smallpox?
a. List t 6 smallpox t 6 as t 6 a t 6 health t 6 orphan t 6 disease.
b. Omit t 6 the t 6 preclinical t 6 research t 6 phase.
c. Extend t 6 the t 6 clinical t 6 research t 6 phase.
d. Fast t 6 track t 6 the t 6 investigational t 6 drug.
ANS: t 6 D
Once t 6 the t 6 Investigational t 6 New t 6 Drug t 6 Application t 6 has t 6 been t 6 approved, t 6 the
t 6 drug t 6 can t 6 recei t 6 ve t 6 highest t 6 priority t 6 within t 6 the t 6 agency, t 6 which t 6 is t 6 called
t 6 fast t 6 tracking. t 6 A t 6 smallpox t 6 outbr t 6 eak t 6 would t 6 become t 6 a t 6 priority t 6 concern
t 6 in t 6 the t 6 world. t 6 Orphan t 6 diseases t 6 are t 6 not t 6 researche
d t 6 in t 6 a t 6 priority t 6 manner. t 6 Preclinical t 6 research t 6 is t 6 not t 6 omitted. t 6 Extending t 6 any
t 6 phase t 6 of t 6 th
e t 6 research t 6 would t 6 mean8ha t 6 longer t 6 time t 6 to t 6 develop t 6 a t 6 vaccine. t 6 The t 6 FDA
t 6 must t 6 ensure t 6 that t6all t6phases t6of t6the t6preclinical t6andclinical t6research t6phase t6have
t6been t6completed t6in t6a t6safe t6manner.
NURSES 19TH EDITIONBY MICHELLE J. WILLIHNGANZ,
SAMUEL L. GUREVITZ, BRUCE CLAYTON COMPLETE
,Chapter 01: Drug Definitions, Standards, and Information Sources Willihn
ganz: Clayton’s Basic Pharmacology for Nurses, 19th Edition
MULTIPLE CHOIC
E
1. Which name identifies a drug listed by the US Foo
d andDrug Administration (FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS: C
The official name is the name under which a drug is
listed by the FDA. The brand name, or trademark, is t
he name given to a drug by its manufacturer. The non
proprietary, or generic, name is provided by the United
States Adopted Names Council.
DIF: Cognitive t 6 Level: t 6 Knowledge REF: t 6 t 6 p. t 6 9
OBJ: t 6 1NAT: t 6 NCLEX t 6 Client t 6 Needs t 6 Category: t 6 Safe,
t 6 Effective t6CareEnvironment t 6 TOP: Nursing t 6 Process
t 6 Step: t 6 Assessment
CON:
Patient t 6 Education
2. Which t 6 source t 6 contains t 6 information t 6 specific t 6 to t 6 nutritional t 6 supplements?
a. USP t 6 Dictionary t 6 of t 6 USAN t 6 & t6International t 6 Drug t 6 Names
b. Natural t 6 Medicines t 6 Comprehensive t 6 Database
c. United t 6 States t 6 Pharmacopoeia/National t 6 Formulary t 6 (USP t 6 NF)
d. Drug t 6 Interaction t 6 Facts
ANS: t 6 C
United t6States t6Pharmacopoeia/National t6Formulary t6contains t6information t6specific t6to
t6nutriti t6onalsupplements. t 6 USP t 6 Dictionary t 6 of t 6 USAN t 6 & t 6 International t 6 Drug
t 6 Names t 6 is t 6 a t 6 compilat t6ion t 6 of t 6 drug8hnames, t 6 pronunciation t 6 guide, t 6 and
t 6 possible t 6 future t 6 FDA t 6 approved t 6 drugs; t 6 it t 6 d t6oes t6not t6include t6nutritional
t6supplements. t6Natural t6Medicines t6Comprehensive t6Database t6c t6ontains
evidence-
based t 6 information t 6 on t 6 herbal t 6 medicines t 6 and t 6 herbal t 6 combination t 6 products; t 6 it
t 6 does t 6 notincl t6ude t 6 information t 6 specific t 6 to t 6 nutritional t 6 supplements. t 6 Drug
t 6 Interaction t 6 Facts t 6 contains t 6 co t6mprehensive t 6 information t 6 on t 6 drug t 6 interaction
t 6 facts; t 6 it t 6 does t 6 not t 6 include t 6 nutritional t 6 supp t 6 lements.
DIF: Cognitive t 6 Level: t 6 Knowledge REF: p. t 6 4
OBJ: t 6 3NAT: t 6 NCLEX t 6 Client t 6 Needs t 6 Category:
t 6 Physiological t6Integrity
TOP: Nursing t 6 Process t 6 Step: t 6 Assessment t 6 CON: Nutrition t 6 | t 6 Patient t 6 Education
3. Which t 6 drug t 6 reference t 6 contains t 6 drug t 6 monographs t 6 that t 6 describe t 6 all t 6 drugs t 6 in t 6 a
therapeutic t 6 class?
t 6
a. Drug t 6 Facts t 6 and t 6 Comparisons
,Test t 6 Bank t 6 For t 6 Clayton’s t 6 Basic t 6 Pharmacology t 6 for 3
t 6 Nurses t 6 19th
b. Drug t 6 Interaction t 6 Facts
c. Handbook t 6 on t 6 Injectable t 6 Drugs
d. Martindale—The t 6 Complete t 6 Drug t 6 Reference
ANS: t 6 A
Drug t 6 Facts t 6 and t 6 Comparisons t 6 contains t 6 drug t 6 monographs t 6 that
t 6 describe t 6 all t 6 drug t6s t 6 in t 6 a8htherapeutic t 6 class. t 6 Monographs t 6 are
t 6 formatted t 6 as t 6 tables t 6 to t 6 allow t 6 compariso t6n t6of t6similarproducts, t6brand
t6names, t6manufacturers, t6cost t6indices, t6and t6available t6d t 6 osage t 6 forms t 6 Online
t 6 version t 6 is t 6 available.
DIF: Cognitive t 6 Level: t 6 Knowledge REF: p. t 6 4 t 6 Table t 6 1.2
OBJ: 3 NAT: t 6 t 6 NCLEX t 6 Client t 6 Needs t 6 Category: t 6 Physiological t 6 Integrity
TOP: Nursing t 6 Process t 6 Step: t 6 Assessment t 6 CON: Safety t 6 | t 6 Patient t 6 Education t 6 | t 6 Clinical
t 6 Judgment
4. Which t 6 drug t 6 reference t 6 contains t 6 monographs t 6 about t 6 virtually t 6 every t 6 single-
entity t6drug t 6 availablein t 6 the t 6 United t 6 States t 6 and t 6 describes t 6 therapeutic t 6 uses t 6 of
t 6 drugs, t 6 incl t6uding t 6 approved t 6 and t 6 unapproved t 6 uses?
a. Martindale: t 6 The t 6 Complete t 6 Drug t 6 Reference
b. AHFS t 6 Drug t 6 Information
c. Drug t 6 Reference
d. Drug t 6 Facts t 6 and t 6 Comparisons
ANS: t 6 B
AHFS t 6 Drug t 6 Information t 6 contains t 6 monographs t 6 about t 6 virtually t 6 every t 6 single-
entity t 6 drug t 6 available t 6 in t 6 the t 6 United t 6 States t 6 and t 6 describes t 6 therapeutic t 6 uses
t 6 of t 6 drugs, t 6 inclu t6ding t 6 approved t 6 and8hunapproved t 6 uses.
DIF: Cognitive t 6 Level: t 6 Knowledge REF: p. t 6 4 t 6 Table t 6 1.2
OBJ: 3 NAT: t 6 t 6 NCLEX t 6 Client t 6 Needs t 6 Category: t 6 Physiological t 6 Integrity
TOP: Nursing t 6 Process t 6 Step: t 6 Planning CON: Safety t 6 | t 6 Patient t 6 Education t 6 | t 6 Clinical
t 6 Judgment
5. Which t 6 online t 6 drug t 6 reference t 6 makes t 6 available t 6 to t 6 healthcare t 6 providers
and t 6 the t 6 publi t6c t 6 a t 6 standard, t 6 comprehensive, t 6 up-to-
t 6
date t 6 look t 6 up t 6 and t 6 downloadable t 6 resource t 6 about t 6 medicines?
a. American t 6 Drug t 6 Index
b. American t 6 Hospital t 6 Formulary
c. DailyMed
d. Drug t 6 Reference
ANS: t 6 C
DailyMed t6makes t6available t6to t6healthcare t6providers t6and t6the t6public t6a t6standard,
t6comprehe t6nsive,8hup-to-
date t 6 look t 6 up t 6 and t 6 downloadable t 6 resource t 6 about t 6 medicines. t 6 The t 6 American
t 6 Drug t 6 Index t 6 i t6snot t 6 appropriate t 6 for t 6 patient t 6 use. t 6 The t 6 American t 6 Hospital
t 6 Formulary t 6 is t 6 not t 6 appropriate t6for t 6 patient t 6 use. t 6 The t 6 drug t 6 reference
t 6 is t 6 not t 6 appropriate t 6 for t 6 patient t 6 use.
DIF: Cognitive t 6 Level: t 6 Knowledge REF: p. t 6 3 t 6 | t 6 p. t 6 4
OBJ: t 6 3NAT: t 6 NCLEX t 6 Client t 6 Needs t 6 Category:
t 6 Physiological t6Integrity
TOP: t 6 Nursing t 6 Process t 6 Step: t 6 Implementation
CON: t 6 t 6 Safety t 6 | t 6 Patient t 6 Education t 6 | t 6 Clinical t 6 Judgment
6. Which t 6 legislation t 6 authorizes t 6 the t 6 FDA t 6 to t 6 determine t 6 the t 6 safety t6of t 6 a t 6 drug t 6 before
its t 6 marketing?
t 6
a. Federal t 6 Food, t 6 Drug, t 6 and t 6 Cosmetic t 6 Act t 6 (1938)
b. Durham t 6 Humphrey t 6 Amendment t 6 (1952)
, Test t 6 Bank t 6 For t 6 Clayton’s t 6 Basic t 6 Pharmacology t 6 for 4
t 6 Nurses t 6 19th
c. Controlled t 6 Substances t 6 Act t 6 (1970)
d. Kefauver t 6 Harris t 6 Drug t 6 Amendment t 6 (1962)
ANS: t 6 A
The t 6 Federal t 6 Food, t 6 Drug, t 6 and t 6 Cosmetic t 6 Act t 6 of t 6 1938 t 6 authorized t 6 the
t 6 FDA t 6 to t 6 determine t 6 the t 6 safety t 6 of t 6 all t 6 drugs t 6 before t 6 marketing. t 6 Later
t 6 amendments t 6 and t 6 acts t 6 helped t 6 tighten t 6 FDA t 6 control t 6 and t 6 ensure t 6 drug
t 6 safety. t 6 The t 6 Durham t 6 Humphrey t 6 Amendment t 6 defines t 6 the t6kinds t 6 of t 6 drugs
t 6 that t 6 cannot t 6 be t 6 used t 6 safely t 6 without t 6 medical t 6 supervision t 6 and t 6 restricts t 6 th
t 6 eir t 6 sale t 6 to t 6 prescription t 6 by t 6 a t 6 licensed t 6 practitioner. t 6 The t 6 Controlled
t 6 Substances t 6 Act t 6 addre t6sses t 6 only t 6 controlled t 6 substances t 6 andtheir
t 6 categorization. t 6 The t 6 Kefauver t 6 Harris t 6 Drug t 6 Ame t6ndment t 6 ensures t 6 drug
t 6 efficacy t 6 and t 6 greaterdrug t 6 safety. t 6 Drug t 6 manufacturers t 6 are t 6 required t6to
t 6 prove t 6 to t 6 the t 6 FDA t 6 the t 6 effectiveness t 6 of t 6 their t 6 products t 6 before
t 6 marketing t 6 them.
DIF: Cognitive t6 Level: t6 Knowledge
REF: t 6 p. t 6 5 t6Table
t 6 l.3 t6OBJ: 5
NAT: t 6 NCLEX t 6 Client t 6 Needs t 6 Category: t6 Physiological t6 Inte
t6grity8hTOP: t 6 Nursing t 6 Process t 6 Step: t 6 Assessment
CON: Safety t 6 | t 6 Patient t 6 Education t 6 | t 6 Evidence t 6 | t 6 Health t 6 Care t 6 Law
7. Which t 6 classification t6 does t 6 meperidine t 6 (Demerol) t 6 fall t 6 under?
a. I
b. II
c. III
d. IV
ANS: t 6 B
Meperidine t 6 (Demerol) t 6 is t 6 a t 6 Schedule t 6 II t 6 drug; t 6 it t 6 has t 6 a t 6 high
t 6 potential t 6 for t 6 abuse t 6 and t 6 m t6ay t 6 lead t 6 tosevere t 6 psychological t 6 and t 6 physical
t 6 dependence. t 6 Schedule t 6 I t 6 drugs t 6 have t 6 high t 6 p t6otential t 6 for t 6 abuseand t 6 no
t 6 recognized t 6 medical t 6 use. t 6 Schedule t 6 III t 6 drugs t 6 have t 6 some t 6 potent t6ial t 6 for
t 6 abuse. t 6 Use t 6 may t 6 lead t 6 to t 6 low t 6 to t 6 moderate t 6 physical t 6 dependence t 6 or t 6 high
t 6 psychol t 6 ogical t 6 dependence. t 6 Schedule t 6 IVdrugs t 6 have t 6 low t 6 potential t 6 for
t 6 abuse. t 6 Use t 6 may t 6 lead t 6 to t 6 limited t 6 physical t 6 or t 6 psychological t 6 dependence.
DIF: Cognitive t 6 Level: t 6 Knowledge REF: p. t 6 10
OBJ: t 6 2NAT: t 6 NCLEX t 6 Client t 6 Needs t 6 Category:
t 6 Safe, t 6 Effectiv t 6 e t 6 Care t 6 Environment
TOP: Nursing t 6 Process t 6 Step: t 6 Assessment t 6 CON: Patient t 6 Education t 6 | t 6 Addiction t6 | t 6 Pain
8. Which t 6 action t 6 would t 6 the t 6 FDA t 6 take t 6 to t 6 expedite t 6 drug t 6 development t 6 and
t6approval t 6 for t 6 an t 6 o t6utbreakof t 6 smallpox?
a. List t 6 smallpox t 6 as t 6 a t 6 health t 6 orphan t 6 disease.
b. Omit t 6 the t 6 preclinical t 6 research t 6 phase.
c. Extend t 6 the t 6 clinical t 6 research t 6 phase.
d. Fast t 6 track t 6 the t 6 investigational t 6 drug.
ANS: t 6 D
Once t 6 the t 6 Investigational t 6 New t 6 Drug t 6 Application t 6 has t 6 been t 6 approved, t 6 the
t 6 drug t 6 can t 6 recei t 6 ve t 6 highest t 6 priority t 6 within t 6 the t 6 agency, t 6 which t 6 is t 6 called
t 6 fast t 6 tracking. t 6 A t 6 smallpox t 6 outbr t 6 eak t 6 would t 6 become t 6 a t 6 priority t 6 concern
t 6 in t 6 the t 6 world. t 6 Orphan t 6 diseases t 6 are t 6 not t 6 researche
d t 6 in t 6 a t 6 priority t 6 manner. t 6 Preclinical t 6 research t 6 is t 6 not t 6 omitted. t 6 Extending t 6 any
t 6 phase t 6 of t 6 th
e t 6 research t 6 would t 6 mean8ha t 6 longer t 6 time t 6 to t 6 develop t 6 a t 6 vaccine. t 6 The t 6 FDA
t 6 must t 6 ensure t 6 that t6all t6phases t6of t6the t6preclinical t6andclinical t6research t6phase t6have
t6been t6completed t6in t6a t6safe t6manner.
